Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBT Margin (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed EBT Margin for 4 consecutive years, with 82.65% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 2183.0% to 82.65% in Q4 2025 year-over-year; TTM through Dec 2025 was 149.16%, a 7940.0% increase, with the full-year FY2025 number at 149.16%, up 7940.0% from a year prior.
  • EBT Margin was 82.65% for Q4 2025 at Iovance Biotherapeutics, up from 138.85% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 82.65% in Q4 2025 to a low of 44960.08% in Q2 2023.
  • A 3-year average of 10109.0% and a median of 239.24% in 2025 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: skyrocketed 4464324bps in 2024, then skyrocketed 642bps in 2025.
  • Iovance Biotherapeutics' EBT Margin stood at 24509.96% in 2023, then soared by 100bps to 104.49% in 2024, then rose by 21bps to 82.65% in 2025.
  • Per Business Quant, the three most recent readings for IOVA's EBT Margin are 82.65% (Q4 2025), 138.85% (Q3 2025), and 182.93% (Q2 2025).